These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19815834)

  • 1. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT; Warburton F; Christou S; Hadjigavriel M; Sitarou M; Kolnagou A; Angastiniotis M
    Haematologica; 2009 Dec; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract]   [Full Text] [Related]  

  • 2. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G; Lindeman R
    Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
    [No Abstract]   [Full Text] [Related]  

  • 3. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ; Kolnagou A
    Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
    [No Abstract]   [Full Text] [Related]  

  • 4. Chelation therapy and bone metabolism markers in thalassemia major.
    Pratelli L; Verri E; Fortini M; Marconi S; Zolezzi C; Fornasari PM; Gamberini MR; De Sanctis V
    J Pediatr Endocrinol Metab; 2006 Nov; 19(11):1335-42. PubMed ID: 17220062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
    Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
    Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y; Evans P; Manz CY; Porter JB
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
    Forni GL; Podestà M; Musso M; Piaggio G; Musallam KM; Balocco M; Pozzi S; Rosa A; Frassoni F
    Haematologica; 2013 Apr; 98(4):555-9. PubMed ID: 23242593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
    Tavecchia L; Masera N; Russo P; Cirò A; Vincenzi A; Vimercati C; Masera G
    Haematologica; 2006 Jun; 91(6 Suppl):ECR19. PubMed ID: 16785138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
    Porter JB; Wood J; Olivieri N; Vichinsky EP; Taher A; Neufeld E; Giardina P; Thompson A; Moore B; Evans P; Kim HY; Macklin EA; Trachtenberg F
    J Cardiovasc Magn Reson; 2013 May; 15(1):38. PubMed ID: 23688265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F; Smith GC; Carpenter JP; Nair SV; Tanner MA; Banya W; Dessi C; Galanello R; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2012 Jan; 14(1):8. PubMed ID: 22277065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
    Kolnagou A; Kontoghiorghes GJ
    Br J Haematol; 2010 Aug; 150(4):489-90; author reply 491. PubMed ID: 20507309
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 18. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 19. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM; Nathan DG; Olivieri NF; Pippard MJ; Weatherall DJ
    Lancet; 2003 Jan; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract]   [Full Text] [Related]  

  • 20. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.